Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-CEL UVEC Cells for Perianal Fistula
NCT07557134Phase 2Not yet recruiting
- Sponsor
- Angiocrine Bioscience
- Start
- May 2027
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in cryptoglandular perianal fistula (2 arms), sponsored by Angiocrine Bioscience. Primary endpoint: Clinical Response Rate at 12 weeks. Planned start May 2027; status: not yet recruiting.
02
Conditions
cryptoglandular perianal fistula
Beyond the preview
Go deeper on NCT07557134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07557134.